7.3119
                                            
            Galecto Inc stock is traded at $7.3119, with a volume of 14,311.
            It is down -0.52% in the last 24 hours and up +96.56% over the past month.
            Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
        
        See More
    Previous Close:
              $7.35
            Open:
              $7.2
            24h Volume:
                14,311
            Relative Volume:
              0.01
            Market Cap:
                $9.68M
            Revenue:
              -
            Net Income/Loss:
              $-38.35M
            P/E Ratio:
              -5.0427
            EPS:
                -1.45
            Net Cash Flow:
                $-36.91M
            1W Performance:
              -13.26%
            1M Performance:
              +96.56%
            6M Performance:
                +161.14%
            1Y Performance:
              +6.74%
            Galecto Inc Stock (GLTO) Company Profile
Name
                  
                      Galecto Inc
                    
                Sector
                  Industry
                  Phone
                  
                      45-70-70-52-10
                    
                Address
                  
                      75 STATE STREET, BOSTON
                    
                Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                GLTO
                            
                             Galecto Inc | 7.31 | 9.74M | 0 | -38.35M | -36.91M | -1.45 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 422.76 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 655.00 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 451.91 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 813.02 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 190.00 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform | 
| Nov-23-20 | Initiated | BofA Securities | Buy | 
| Nov-23-20 | Initiated | Credit Suisse | Outperform | 
| Nov-23-20 | Initiated | SVB Leerink | Outperform | 
Galecto Inc Stock (GLTO) Latest News
Can Galecto Inc. stock weather global recessionJuly 2025 Update & AI Forecast Swing Trade Picks - newser.com
Combining price and volume data for Galecto Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
How to monitor Galecto Inc. with trend dashboardsQuarterly Earnings Summary & Safe Entry Zone Identification - newser.com
Will Galecto Inc. stock maintain dividend yieldTrade Entry Report & Weekly Chart Analysis and Guides - newser.com
Is a relief rally coming for Galecto Inc. holdersJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Can Galecto Inc. stock hit analyst price targetsTrade Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Is Galecto Inc. stock cheap at current valuationQuarterly Growth Report & High Accuracy Investment Entry Signals - newser.com
Why Galecto Inc. stock remains undervalued2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Is Galecto Inc. stock attractive for income investorsJuly 2025 Update & Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Using portfolio simulators with Galecto Inc. includedQuarterly Performance Summary & Fast Moving Market Watchlists - newser.com
What drives Galecto Inc stock priceRisk-Reward Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Galecto Inc. stock attractive for growth ETFsTrade Volume Summary & Verified Swing Trading Watchlist - newser.com
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galecto Inc Stock (GLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | 
|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel | Jul 03 '25 | Sale | 3.39 | 260 | 881 | 1,429 | 
| Firmani Lori | Interim CFO | Jul 03 '25 | Sale | 3.39 | 147 | 498 | 692 | 
| Winslow Garrett | General Counsel | Jan 03 '25 | Sale | 5.60 | 471 | 2,638 | 1,009 | 
| Firmani Lori | Interim CFO | Jan 03 '25 | Sale | 5.63 | 261 | 1,469 | 465 | 
| Schambye Hans T. | Chief Executive Officer | Jan 03 '25 | Sale | 5.60 | 1,341 | 7,510 | 3,397 | 
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):
                 
            
         
                     
                             Get the Stockscreener App
                    Get the Stockscreener App